These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 31730533)
1. Significance of the routine first-trimester antenatal screening program for aneuploidy in the assessment of the risk of placenta accreta spectrum disorders. Penzhoyan GA; Makukhina TB J Perinat Med; 2019 Dec; 48(1):21-26. PubMed ID: 31730533 [TBL] [Abstract][Full Text] [Related]
3. Relationship between first trimester aneuploidy screening test serum analytes and placenta accreta. Büke B; Akkaya H; Demir S; Sağol S; Şimşek D; Başol G; Barutçuoğlu B J Matern Fetal Neonatal Med; 2018 Jan; 31(1):59-62. PubMed ID: 28027672 [TBL] [Abstract][Full Text] [Related]
4. Lower uterine segment scar assessment at 11-14 weeks' gestation to screen for placenta accreta spectrum in women with prior Cesarean delivery. Bhatia A; Palacio M; Wright AM; Yeo GSH Ultrasound Obstet Gynecol; 2022 Jan; 59(1):40-48. PubMed ID: 34254386 [TBL] [Abstract][Full Text] [Related]
5. First trimester maternal serum biochemical markers of aneuploidy in pregnancies with abnormally invasive placentation. Thompson O; Otigbah C; Nnochiri A; Sumithran E; Spencer K BJOG; 2015 Sep; 122(10):1370-6. PubMed ID: 25639820 [TBL] [Abstract][Full Text] [Related]
6. Elevated first-trimester PAPP-A is a marker in high-risk pregnancies with an increased risk of placenta accreta in predicting adverse outcomes. Balkaş G; Çaglar T Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):9955-9961. PubMed ID: 37916365 [TBL] [Abstract][Full Text] [Related]
7. First trimester serum PAPP-A is associated with placenta accreta: a retrospective study. Wang F; Chen S; Wang J; Wang Y; Ruan F; Shu H; Zhu L; Man D Arch Gynecol Obstet; 2021 Mar; 303(3):645-652. PubMed ID: 33515274 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of contingent screening for placenta accreta spectrum disorders based on persistent low-lying placenta and previous uterine surgery. Coutinho CM; Giorgione V; Noel L; Liu B; Chandraharan E; Pryce J; Frick AP; Thilaganathan B; Bhide A Ultrasound Obstet Gynecol; 2021 Jan; 57(1):91-96. PubMed ID: 32865834 [TBL] [Abstract][Full Text] [Related]
9. First-trimester ultrasound diagnostic features of placenta accreta spectrum in low-implantation pregnancy. Abinader RR; Macdisi N; El Moudden I; Abuhamad A Ultrasound Obstet Gynecol; 2022 Apr; 59(4):457-464. PubMed ID: 34837427 [TBL] [Abstract][Full Text] [Related]
10. Value of first-trimester ultrasound in prediction of third-trimester sonographic stage of placenta accreta spectrum disorder and surgical outcome. Calí G; Timor-Tritsch IE; Forlani F; Palacios-Jaraquemada J; Monteagudo A; Kaelin Agten A; Flacco ME; Khalil A; Buca D; Manzoli L; Liberati M; D'Antonio F Ultrasound Obstet Gynecol; 2020 Apr; 55(4):450-459. PubMed ID: 31788885 [TBL] [Abstract][Full Text] [Related]
12. Maternal plasma levels of cell-free β-HCG mRNA as a prenatal diagnostic indicator of placenta accrete. Zhou J; Li J; Yan P; Ye YH; Peng W; Wang S; Wang XT Placenta; 2014 Sep; 35(9):691-5. PubMed ID: 25063251 [TBL] [Abstract][Full Text] [Related]
13. Diagnostic Role of Cell-Free miRNAs in Identifying Placenta Accreta Spectrum during First-Trimester Screening. Timofeeva AV; Fedorov IS; Suhova YV; Tarasova AM; Ezhova LS; Zabelina TM; Vasilchenko ON; Ivanets TY; Sukhikh GT Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255950 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of distal haemostasis during caesarean delivery in women with placenta accreta spectrum disorders. Barinov SV; Shmakov RG; Medyannikova IV; Tirskaya YI; Kadtsyna TV; Lazareva OV; Razdobedina IN; Neustroyeva TN; Stepanov SS J Matern Fetal Neonatal Med; 2022 Dec; 35(25):8778-8785. PubMed ID: 34794371 [TBL] [Abstract][Full Text] [Related]